Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore. Show more
Marina One East Tower, Singapore, 018936, Singapore
Market Cap
2.451B
52 Wk Range
$5.28 - $21.73
Previous Close
$13.02
Open
$13.12
Volume
2,608,740
Day Range
$12.38 - $13.38
Enterprise Value
1.867B
Cash
602.1M
Avg Qtr Burn
-33.78M
Insider Ownership
14.13%
Institutional Own.
88.38%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
WVE-N531 Details Duchenne muscular dystrophy | NDA Submission | |
WVE-006 Details Alpha-1 Antitrypsin Deficiency | Phase 1/2 Data readout | |
Phase 1 Data readout | ||
WVE-003 Details Huntington's disease | IND Submission | |
WVE-008 Details PNPLA3-I148M liver disease | IND Submission | |
WVE-120101 (SNP1) Details Huntington's disease | Failed Discontinued | |
WVE-120102 (SNP2) Details Huntington's disease | Failed Discontinued | |
WVE-004 Details Amyotrophic lateral sclerosis, Frontotemporal dementia with GRN mutations | Failed Discontinued |
